Supernus Pharmaceuticals, Inc. (SUPN)
US — Healthcare Sector
Automate Your Wheel Strategy on SUPN
With Tiblio's Option Bot, you can configure your own wheel strategy including SUPN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SUPN
- Rev/Share 11.872
- Book/Share 18.9898
- PB 2.6496
- Debt/Equity 0.0299
- CurrentRatio 2.5802
- ROIC 0.0449
- MktCap 2821362281.0
- FreeCF/Share 3.3176
- PFCF 15.1796
- PE 43.7064
- Debt/Assets 0.023
- DivYield 0
- ROE 0.0624
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 4
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | SUPN | Piper Sandler | Neutral | Overweight | -- | $65 | Oct. 9, 2025 |
| Upgrade | SUPN | Cantor Fitzgerald | Neutral | Overweight | -- | $42 | July 30, 2025 |
| Downgrade | SUPN | Cantor Fitzgerald | Overweight | Neutral | $57 | $36 | Feb. 19, 2025 |
| Initiation | SUPN | Cantor Fitzgerald | -- | Overweight | -- | $57 | Jan. 6, 2025 |
| Downgrade | SUPN | Piper Sandler | Overweight | Neutral | $41 | $36 | Sept. 11, 2024 |
News
Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
SUPN
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
ROCKVILLE, Md., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the fourth quarter and full year of 2024 after the market closes on Tuesday, February 25, 2025.
Read More
About Supernus Pharmaceuticals, Inc. (SUPN)
- IPO Date 2012-05-01
- Website https://www.supernus.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Jack A. Khattar
- Employees 674
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.